PMED-1 is a β-catenin inhibitor that significantly reduces β-catenin activity in hepatoblastoma cells and various HCC cells, with an IC50 value ranging from 4.87 to 32 μM. PMED-1 affects Wnt signaling by decreasing the interaction between β-catenin and CREB binding protein, thereby inhibiting cell proliferation. PMED-1 has potential applications in cancer research[1].
References
[1] Delgado ER, et al. Identification and characterization of a novel small-molecule inhibitor of β-catenin signaling. Am J Pathol. 2014 Jul;184(7):2111-22. DOI:10.1016/j.ajpath.2014.04.002
